Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE0005785604
Tue, 07.05.2024
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA: Fresenius raises outlook for fiscal year 2024
Fresenius raises its full-year outlook due to the excellent first quarter and a better than originally expected operating performance for the remainder of the fiscal year 2024.
Fresenius now expects organic group revenue growth between 4 and 7% for the fiscal year 2024 (pre [ … ]
Tue, 05.12.2023
Fresenius SE & Co. KGaA
Fresenius retains relief payments for hospitals of up to €300 million (from the current perspective) and is therefore subject to a ban on dividends and bonuses for 2023
The Management Board of Fresenius Management SE decided today that Fresenius Group will retain the governmental compensation and reimbursement payments of up to €300 million (from t [ … ]
Tue, 21.02.2023
Fresenius SE & Co. KGaA
Fresenius has set the strategic course for simplifying the Group structure. As part of a comprehensive range of initiatives, the management board of Fresenius Management SE has also put in place a new financial framework. For 2023, Fresenius now provides full-year guidance for organic sales growth and operating income (EBIT). For 2023, Fresenius ex [ … ]
Tue, 21.02.2023
Fresenius SE & Co. KGaA
Fresenius has set the strategic course for simplifying the Group structure. As part of a comprehensive range of initiatives, the management board of Fresenius Management SE has also put in place a new financial framework. For 2023, Fresenius now provides full-year guidance for organic sales growth and operating income (EBIT). For 2023, Fresenius ex [ … ]
Thu, 09.02.2023
Fresenius SE & Co. KGaA
As part of the „strategic review” initiated by Michael Sen, Chief Executive Officer of Fresenius SE & Co. KGaA (“the Issuer”), the Issuer is also analyzing the deconsolidation of its subsidiary Fresenius Medical Care AG & Co. KGaA (“FMC”), amongst other ways, through a change of the legal form into a stock corporation (Aktiengesellschaft).
[ … ]
Thu, 09.02.2023
Fresenius SE & Co. KGaA
As part of the „strategic review” initiated by Michael Sen, Chief Executive Officer of Fresenius SE & Co. KGaA (“the Issuer”), the Issuer is also analyzing the deconsolidation of its subsidiary Fresenius Medical Care AG & Co. KGaA (“FMC”), amongst other ways, through a change of the legal form into a stock corporation (Aktiengesellschaft).
[ … ]
Mon, 05.12.2022
Fresenius SE & Co. KGaA
Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
Today, the Supervisory Board of Fresenius Medical Care Management AG, the General Partner of Fresenius Medical Care AG & Co. KGaA, has unanimously appointed Helen Giza as CEO of the Management Board with effect as of 6 December 2022. Helen Giza continues to [ … ]
Mon, 05.12.2022
Fresenius SE & Co. KGaA
Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company
Today, the Supervisory Board of Fresenius Medical Care Management AG, the General Partner of Fresenius Medical Care AG & Co. KGaA, has unanimously appointed Helen Giza as CEO of the Management Board with effect as of 6 December 2022. Helen Giza continues to [ … ]
Sun, 30.10.2022
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA: Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised
Since Fresenius Medical Care continues to operate in a challenging environment, the impacts of the Company’s focused efforts to improve North American Health Care [ … ]
Sun, 30.10.2022
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA: Challenging macroeconomic environment impact Fresenius Medical Care and Fresenius Group earnings in FY/22; Fresenius SE & Co. KGaA Group guidance revised
Since Fresenius Medical Care continues to operate in a challenging environment, the impacts of the Company’s focused efforts to improve North American Health Care [ … ]